Skip to content
Screener

Upstream Bio, Inc. UPB Enterprise value

Enterprise value at other companies

Amgen logo
AmgenAMGN
$252.17B+23.1%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$65.61B+15.0%
Aclaris Therapeutics logo
Aclaris TherapeuticsACRS
$721.5M+410%
Shattuck Labs, Inc. logo
Shattuck Labs, Inc.STTK
$602.2M+28,785%
Savara logo
SavaraSVRA
$1.25B+208%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$1.35B+176%

Other financials

Income statement

See full
Revenue$773.0K-17.5%
Operating income-$42.4M+4.5%
Net income-$39.7M+0.7%
EPS (diluted)-$0.73+1.4%

Balance sheet

See full
Cash & equivalents$79.4M+74.7%
Total debt$954.0K-38.9%
Total equity$271.0M-33.7%
Total assets$281.2M-33.1%

Cash flow

See full
Operating cash flow-$35.6M+9.2%
CapEx$54.0K-70.8%
Free cash flow-$30.7M-55.0%

Valuation

See full
Market cap$394.54M-54.7%
P/S124.9×-195×

Profitability

See full
Operating margin-5,382.6%+1,393pp
Net margin-4,955.7%+2,041pp

Returns & leverage

See full
Return on equity-46%
Debt / equity0.0×
Current ratio28×-10.3×

Where this comes from

Calculated from Upstream Bio, Inc.’s reported figures.

The source filing: Upstream Bio, Inc.’s 10-Q, filed August 11, 2026. Open the filing →

Filed
Aug 11, 2026, 7:10 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-343417

FAQ

What is Upstream Bio, Inc.'s enterprise value?
Upstream Bio, Inc. (UPB) reported enterprise value of $298.14M in Q2 2026.
How has Upstream Bio, Inc.'s enterprise value changed year-over-year?
Upstream Bio, Inc.'s enterprise value decreased by 47.6% year-over-year, from $568.81M to $298.14M.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.

Ask your AI about Upstream Bio, Inc.'s enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude